Clinical Trial Update: PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pegylated interferon alfa-2b in combination with thalidomide for patients with recurrent or metastatic melanoma. The study includes bot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Intraocular Melanoma

Drugs mentioned

• PEG-Interferon alfa-2b (pegylated interferon alfa-2b)
• Thalidomide (thalidomide)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Status: COMPLETED